BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sakashita M, Aoyama N, Minami R, Maekawa S, Kuroda K, Shirasaka D, Ichihara T, Kuroda Y, Maeda S, Kasuga M. Glut1 expression in T1 and T2 stage colorectal carcinomas: its relationship to clinicopathological features. Eur J Cancer. 2001;37:204-209. [PMID: 11166147 DOI: 10.1016/s0959-8049(00)00371-3] [Cited by in Crossref: 54] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Shim BY, Jung JH, Lee KM, Kim HJ, Hong SH, Kim SH, Sun DS, Cho HM. Glucose transporter 1 (GLUT1) of anaerobic glycolysis as predictive and prognostic values in neoadjuvant chemoradiotherapy and laparoscopic surgery for locally advanced rectal cancer. Int J Colorectal Dis. 2013;28:375-383. [PMID: 22847606 DOI: 10.1007/s00384-012-1542-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
2 De Castro F, Benedetti M, Del Coco L, Fanizzi FP. NMR-Based Metabolomics in Metal-Based Drug Research. Molecules 2019;24:E2240. [PMID: 31208065 DOI: 10.3390/molecules24122240] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
3 Glasgow SC, Bleier JI, Burgart LJ, Finne CO, Lowry AC. Meta-analysis of histopathological features of primary colorectal cancers that predict lymph node metastases. J Gastrointest Surg. 2012;16:1019-1028. [PMID: 22258880 DOI: 10.1007/s11605-012-1827-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 6.1] [Reference Citation Analysis]
4 Furuta E, Okuda H, Kobayashi A, Watabe K. Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim Biophys Acta 2010;1805:141-52. [PMID: 20122995 DOI: 10.1016/j.bbcan.2010.01.005] [Cited by in Crossref: 47] [Cited by in F6Publishing: 129] [Article Influence: 4.3] [Reference Citation Analysis]
5 Sakamoto K, Takahashi M, Yaginuma Y, Ishido Y, Matsuoka T, Sakamoto S, Tomiki Y, Kamano T. Early colon cancer detected by 18F-FDG PET. Int J Gastrointest Cancer 2005;36:95-8. [PMID: 16648659 DOI: 10.1385/IJGC:36:2:95] [Reference Citation Analysis]
6 Krzeslak A, Wojcik-Krowiranda K, Forma E, Jozwiak P, Romanowicz H, Bienkiewicz A, Brys M. Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers. Pathol Oncol Res. 2012;18:721-728. [PMID: 22270867 DOI: 10.1007/s12253-012-9500-5] [Cited by in Crossref: 141] [Cited by in F6Publishing: 145] [Article Influence: 15.7] [Reference Citation Analysis]
7 Malone CF, Fromm JA, Maertens O, DeRaedt T, Ingraham R, Cichowski K. Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers. Cancer Discov 2014;4:1062-73. [PMID: 24913553 DOI: 10.1158/2159-8290.CD-14-0159] [Cited by in Crossref: 41] [Cited by in F6Publishing: 29] [Article Influence: 5.9] [Reference Citation Analysis]
8 Kang SS, Chun YK, Hur MH, Lee HK, Kim YJ, Hong SR, Lee JH, Lee SG, Park YK. Clinical significance of glucose transporter 1 (GLUT1) expression in human breast carcinoma. Jpn J Cancer Res 2002;93:1123-8. [PMID: 12417042 DOI: 10.1111/j.1349-7006.2002.tb01214.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 85] [Article Influence: 4.4] [Reference Citation Analysis]
9 Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, Schmidt K, Willson JK, Markowitz S, Zhou S, Diaz LA Jr, Velculescu VE, Lengauer C, Kinzler KW, Vogelstein B, Papadopoulos N. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science. 2009;325:1555-1559. [PMID: 19661383 DOI: 10.1126/science.1174229] [Cited by in Crossref: 610] [Cited by in F6Publishing: 529] [Article Influence: 50.8] [Reference Citation Analysis]
10 Lee JH, Lee WA, Park SG, Park DK, Namgung H. Relationship Between Dual-Time Point FDG PET and Immunohistochemical Parameters in Preoperative Colorectal Cancer: Preliminary Study. Nucl Med Mol Imaging 2012;46:48-56. [PMID: 24900032 DOI: 10.1007/s13139-011-0120-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
11 Airley R, Evans A, Mobasheri A, Hewitt SM. Glucose transporter Glut-1 is detectable in peri-necrotic regions in many human tumor types but not normal tissues: Study using tissue microarrays. Ann Anat 2010;192:133-8. [PMID: 20395120 DOI: 10.1016/j.aanat.2010.03.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
12 GabAllah GMK, El-Din Habib MS, Soliman SE, Kasemy ZA, Gohar SF. Validity and clinical impact of glucose transporter 1 expression in colorectal cancer. Saudi J Gastroenterol 2017;23:348-56. [PMID: 29205188 DOI: 10.4103/sjg.SJG_197_17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
13 Yao Z, Xie F, Li M, Liang Z, Xu W, Yang J, Liu C, Li H, Zhou H, Qu LH. Oridonin induces autophagy via inhibition of glucose metabolism in p53-mutated colorectal cancer cells. Cell Death Dis 2017;8:e2633. [PMID: 28230866 DOI: 10.1038/cddis.2017.35] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 13.0] [Reference Citation Analysis]
14 Stahl T, Hümmer S, Ehrenfeuchter N, Mittal N, Fucile G, Spang A. Asymmetric distribution of glucose transporter mRNA provides a growth advantage in yeast. EMBO J 2019;38:e100373. [PMID: 30910878 DOI: 10.15252/embj.2018100373] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
15 Strauss LG, Klippel S, Pan L, Schönleben K, Haberkorn U, Dimitrakopoulou-Strauss A. Assessment of quantitative FDG PET data in primary colorectal tumours: which parameters are important with respect to tumour detection? Eur J Nucl Med Mol Imaging. 2007;34:868-877. [PMID: 17219134 DOI: 10.1007/s00259-006-0319-8] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
16 Saigusa S, Toiyama Y, Tanaka K, Okugawa Y, Fujikawa H, Matsushita K, Uchida K, Inoue Y, Kusunoki M. Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy. Surg Today 2012;42:460-9. [PMID: 22072148 DOI: 10.1007/s00595-011-0027-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
17 Adekola K, Rosen ST, Shanmugam M. Glucose transporters in cancer metabolism. Curr Opin Oncol. 2012;24:650-654. [PMID: 22913968 DOI: 10.1097/cco.0b013e328356da72] [Cited by in Crossref: 181] [Cited by in F6Publishing: 109] [Article Influence: 22.6] [Reference Citation Analysis]
18 Jadvar H, Alavi A, Gambhir SS. 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med 2009;50:1820-7. [PMID: 19837767 DOI: 10.2967/jnumed.108.054098] [Cited by in Crossref: 154] [Cited by in F6Publishing: 142] [Article Influence: 12.8] [Reference Citation Analysis]
19 Lee JE, Kim SW, Kim JS, Choi KY, Kang WK, Oh ST, Yoo IR, Kim SH. Prognostic value of 18-fluorodeoxyglucose positron emission tomography-computed tomography in resectable colorectal cancer. World J Gastroenterol 2012; 18(36): 5072-5077 [PMID: 23049216 DOI: 10.3748/wjg.v18.i36.5072] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
20 Patergnani S, Bouhamida E, Leo S, Pinton P, Rimessi A. Mitochondrial Oxidative Stress and "Mito-Inflammation": Actors in the Diseases. Biomedicines 2021;9:216. [PMID: 33672477 DOI: 10.3390/biomedicines9020216] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
21 Potter M, Newport E, Morten KJ. The Warburg effect: 80 years on. Biochem Soc Trans 2016;44:1499-505. [PMID: 27911732 DOI: 10.1042/BST20160094] [Cited by in Crossref: 197] [Cited by in F6Publishing: 121] [Article Influence: 49.3] [Reference Citation Analysis]
22 Rendic S, Guengerich FP. Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters. Curr Drug Metab 2010;11:4-84. [PMID: 20302566 DOI: 10.2174/138920010791110917] [Cited by in Crossref: 76] [Cited by in F6Publishing: 64] [Article Influence: 6.9] [Reference Citation Analysis]
23 Zhang Y, Qiu W, Zhang M, Zhang L, Zhang X. MnO 2 Motor: A Prospective Cancer-Starving Therapy Promoter. ACS Appl Mater Interfaces 2018;10:15030-9. [DOI: 10.1021/acsami.8b01818] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 18.0] [Reference Citation Analysis]
24 Chen X, Zhao Y, Lyu S, Gao G, Gao Y, Qi Y, Du J. Identification of novel inhibitors of GLUT1 by virtual screening and cell-based assays. Invest New Drugs 2021. [PMID: 33900490 DOI: 10.1007/s10637-021-01109-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Zambrano A, Molt M, Uribe E, Salas M. Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy. Int J Mol Sci 2019;20:E3374. [PMID: 31324056 DOI: 10.3390/ijms20133374] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 18.0] [Reference Citation Analysis]
26 Parente P, Coli A, Massi G, Mangoni A, Fabrizi MM, Bigotti G. Immunohistochemical expression of the glucose transporters Glut-1 and Glut-3 in human malignant melanomas and benign melanocytic lesions. J Exp Clin Cancer Res 2008;27:34. [PMID: 18764953 DOI: 10.1186/1756-9966-27-34] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
27 Jang SM, Han H, Jang KS, Jun YJ, Jang SH, Min KW, Chung MS, Paik SS. The Glycolytic Phenotype is Correlated with Aggressiveness and Poor Prognosis in Invasive Ductal Carcinomas. J Breast Cancer 2012;15:172-80. [PMID: 22807934 DOI: 10.4048/jbc.2012.15.2.172] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
28 Jun YJ, Jang SM, Han HL, Lee KH, Jang KS, Paik SS. Clinicopathologic significance of GLUT1 expression and its correlation with Apaf-1 in colorectal adenocarcinomas. World J Gastroenterol 2011; 17(14): 1866-1873 [PMID: 21528061 DOI: 10.3748/wjg.v17.i14.1866] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
29 Hong R, Lim SC. 18F-fluoro-2-deoxyglucose uptake on PET CT and glucose transporter 1 expression in colorectal adenocarcinoma. World J Gastroenterol 2012; 18(2): 168-174 [PMID: 22253523 DOI: 10.3748/wjg.v18.i2.168] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
30 Wincewicz A, Sulkowska M, Koda M, Sulkowski S. Clinicopathological significance and linkage of the distribution of HIF-1alpha and GLUT-1 in human primary colorectal cancer. Pathol Oncol Res 2007;13:15-20. [PMID: 17387384 DOI: 10.1007/BF02893436] [Cited by in Crossref: 31] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
31 Koch A, Lang SA, Wild PJ, Gantner S, Mahli A, Spanier G, Berneburg M, Müller M, Bosserhoff AK, Hellerbrand C. Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells. Oncotarget 2015;6:32748-60. [PMID: 26293674 DOI: 10.18632/oncotarget.4977] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 10.8] [Reference Citation Analysis]
32 Wang Y, Yun Y, Wu B, Wen L, Wen M, Yang H, Zhao L, Liu W, Huang S, Wen N, Li Y. FOXM1 promotes reprogramming of glucose metabolism in epithelial ovarian cancer cells via activation of GLUT1 and HK2 transcription. Oncotarget 2016;7:47985-97. [PMID: 27351131 DOI: 10.18632/oncotarget.10103] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
33 Sieber-Frank J, Stark HJ, Kalteis S, Prigge ES, Köhler R, Andresen C, Henkel T, Casari G, Schubert T, Fischl W, Li-Weber M, Krammer PH, von Knebel Doeberitz M, Kopitz J, Kloor M, Ahadova A. Treatment resistance analysis reveals GLUT-1-mediated glucose uptake as a major target of synthetic rocaglates in cancer cells. Cancer Med 2021;10:6807-22. [PMID: 34546000 DOI: 10.1002/cam4.4212] [Cited by in F6Publishing: 1] [Reference Citation Analysis]